Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2016
Here are the related meetings in 2021:
MEETING CHANGE TO VIRTUAL: Tuberculosis: Science Aimed at Ending the Epidemic (S9)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Tuberculosis Co-Morbidities and Immunopathogenesis (B6)
Organizer(s) Hardy Kornfeld, Sarah M. Fortune and Thomas R. Hawn
February 28—March 3, 2016
Keystone Resort • Keystone, CO USA
Discounted Abstract Deadline: Oct 29, 2015
Abstract Deadline: Dec 1, 2015
Scholarship Deadline: Oct 29, 2015
Discounted Registration Deadline: Jan 5, 2016
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
Tuberculosis remains one of the most significant infectious disease threats to global health despite the availability of effective antimicrobials for more than 50 years. The focus of this Keystone Symposia meeting is on co-morbidities that are major driving factors in the TB pandemic and that may cause informative perturbations of immunity. This symposium explores metabolic disorders, environmental exposures, co-infections, age and genetic variants that influence host-pathogen interactions in TB. Plenary sessions will combine rather than separate topics focused on the host and the pathogen, and perspectives from laboratory and field studies. Speakers are encouraged to challenge existing dogma and offer new paradigms as a basis for more effective approaches to TB prevention and treatment.
View Scholarships/Awards
Tuberculosis remains one of the most significant infectious disease threats to global health despite the availability of effective antimicrobials for more than 50 years. The focus of this Keystone Symposia meeting is on co-morbidities that are major driving factors in the TB pandemic and that may cause informative perturbations of immunity. This symposium explores metabolic disorders, environmental exposures, co-infections, age and genetic variants that influence host-pathogen interactions in TB. Plenary sessions will combine rather than separate topics focused on the host and the pathogen, and perspectives from laboratory and field studies. Speakers are encouraged to challenge existing dogma and offer new paradigms as a basis for more effective approaches to TB prevention and treatment.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, February 28 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 3 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 4 in order to fully experience the meeting.
SUNDAY, FEBRUARY 28
MONDAY, FEBRUARY 29
TUESDAY, MARCH 1
WEDNESDAY, MARCH 2
THURSDAY, MARCH 3
FRIDAY, MARCH 4
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, February 28 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 3 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 4 in order to fully experience the meeting.
SUNDAY, FEBRUARY 28
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Metabolism and Co-Morbidity I
*
Eric J. Rubin,
Harvard T.H. Chan School of Public Health, USA
Gökhan S. Hotamisligil,
Harvard School of Public Health, USA
Immunometabolic Homeostasis and Metaflammation in Health and Disease
Immunometabolic Homeostasis and Metaflammation in Health and Disease
Larry S. Schlesinger,
Texas Biomedical Research Institute, USA
A Convergence of Macrophage Inflammation and Metabolism
A Convergence of Macrophage Inflammation and Metabolism
Kyu Y. Rhee,
Weill Cornell Medical College, USA
Bacterial Metabolism in a Changing Host Environment
Bacterial Metabolism in a Changing Host Environment
Sarah A. Stanley,
University of California, Berkeley, USA
An Immune-Metabolic Program Regulated by HIF-1alpha and Nitric Oxide is Required for Control of M. tuberculosis
An Immune-Metabolic Program Regulated by HIF-1alpha and Nitric Oxide is Required for Control of M. tuberculosis
Noton K. Dutta,
Johns Hopkins School of Medicine, USA
Short Talk: Statin Adjunctive Therapy Shortens the Duration of Tuberculosis Treatment in Mice
Short Talk: Statin Adjunctive Therapy Shortens the Duration of Tuberculosis Treatment in Mice
14:30—16:30
Workshop 1: TB Risk Factors
*
Georgiana Purdy,
Oregon Health & Sciences University, USA
Abul K. Azad,
Ohio State University, USA
Defining the Genetic Basis for Biological Variation Among Donors in Human Macrophage Responses to Mycobacterium Tuberculosis
Defining the Genetic Basis for Biological Variation Among Donors in Human Macrophage Responses to Mycobacterium Tuberculosis
Anthony Michael Cadena,
University of Pittsburgh School of Medicine, USA
Barcoding Mycobacterium Tuberculosis Reveals Local in vivo Infection Dynamics in the Macaque Model of Tuberculosis
Barcoding Mycobacterium Tuberculosis Reveals Local in vivo Infection Dynamics in the Macaque Model of Tuberculosis
Mark Hatherill,
University of Cape Town, South Africa
A Phase 2 Randomized Controlled Trial of Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin (BCG) Vaccination in Infants of HIV Infected Mothers
A Phase 2 Randomized Controlled Trial of Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin (BCG) Vaccination in Infants of HIV Infected Mothers
David J. Horne,
University of Washington, USA
Human ULK1 Variation and Susceptibility to Latent Tuberculosis Infection
Human ULK1 Variation and Susceptibility to Latent Tuberculosis Infection
Nuria Martinez,
University of Massachusetts Medical School, USA
Impaired Innate Recognition of Mycobacterium tuberculosis by Alveolar Macrophages from Diabetic Mice
Impaired Innate Recognition of Mycobacterium tuberculosis by Alveolar Macrophages from Diabetic Mice
Juan I. Moliva,
Vaccine Research Center, USA
Age-Associated Oxidation of Innate Immune Proteins in the Lung Mucosa Alters the Host Response to Mycobacterium tuberculosis
Age-Associated Oxidation of Innate Immune Proteins in the Lung Mucosa Alters the Host Response to Mycobacterium tuberculosis
Ruijuan Zheng,
Tongii University School of Medicine, China
Induction of Notch4 Negatively Regulate the Inflammatory responses to Mycobacterium Tuberculosis Infection
Induction of Notch4 Negatively Regulate the Inflammatory responses to Mycobacterium Tuberculosis Infection
17:00—19:00
Genetic Variation: A Different Type of Co-Morbidity?
*
Ann M. Ginsberg,
Bill & Melinda Gates Foundation, USA
Thomas R. Hawn,
University of Washington, USA
Innate Resistance to Mtb Infection
Innate Resistance to Mtb Infection
Igor B. Kramnik,
Boston University, USA
Control of Lung Damage and Carcinogenesis in TB: Genes Meet the Microenvironment
Control of Lung Damage and Carcinogenesis in TB: Genes Meet the Microenvironment
Sarah M. Fortune,
Harvard TH Chan School of Public Health, USA
Identifying the Drivers of Genetic Variation in Clinical Isolates of Mycobacterium tuberculosis
Identifying the Drivers of Genetic Variation in Clinical Isolates of Mycobacterium tuberculosis
Maria Lerm,
Linkoping University, Sweden
Short Talk: Epigenetic Reprogramming of Peripheral Blood Mononuclear Cells in BCG-Vaccinated Individuals
Short Talk: Epigenetic Reprogramming of Peripheral Blood Mononuclear Cells in BCG-Vaccinated Individuals
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
HIV/TB Co-Morbidity
*
Michael Stephen Glickman,
Memorial Sloan-Kettering Institute, USA
Robert J. Wilkinson,
University of Cape Town, South Africa
Understanding and Intervening in HIV-Associated Tuberculosis
Understanding and Intervening in HIV-Associated Tuberculosis
Anne E. Goldfeld,
Children's Hospital Boston, Harvard Medical School, USA
Time is of the Essence: Lessons from the CAMELIA Trial
Time is of the Essence: Lessons from the CAMELIA Trial
Keertan Dheda,
University of Cape Town, South Africa
New Insights into the Pathogenesis of Drug-Resistant TB and Implications for Clinical Management
New Insights into the Pathogenesis of Drug-Resistant TB and Implications for Clinical Management
Philana Ling Lin,
University of Pittsburgh, USA
Lesion Dynamics in SIV/TB Co-Infection
Lesion Dynamics in SIV/TB Co-Infection
Elisa Nemes,
University of Cape Town, South Africa
Short Talk: Host Correlates of Risk of Bacille Calmette-Guerin (BCG) Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV+ Children Starting Antiretroviral Therapy (ART)
Short Talk: Host Correlates of Risk of Bacille Calmette-Guerin (BCG) Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV+ Children Starting Antiretroviral Therapy (ART)
Robert Blomgran,
Linköping University, Sweden
Short Talk: HIV Interferes with Mycobacterium Tuberculosis Antigen Presentation in Human Dendritic Cells
Short Talk: HIV Interferes with Mycobacterium Tuberculosis Antigen Presentation in Human Dendritic Cells
11:30—12:15
Tips for Writing NIH Grant Applications: Navigating NIH Peer Review
*
Raymond R. Schleef,
NIAID, National Institutes of Health, USA
14:30—16:30
Workshop 2: Host-Pathogen Interactions
*
David M. Tobin,
Duke University School of Medicine, USA
Eusondia Arnett,
Texas Biomedical Research Institute, USA
Characterization of Virulence-Dependent AIM2 Expression, a PPAR-gamma effector in Human Macrophages During Mycobacterium Infection
Characterization of Virulence-Dependent AIM2 Expression, a PPAR-gamma effector in Human Macrophages During Mycobacterium Infection
Claire Dodd,
Ohio State University, USA
Scavenger Receptor CD36 Mediates Uptake of Surfactant Lipids by Human Macrophages and Regulates Intracellular Growth of M. tuberculosis
Scavenger Receptor CD36 Mediates Uptake of Surfactant Lipids by Human Macrophages and Regulates Intracellular Growth of M. tuberculosis
Jan Philipp Korte,
Heinrich-Heine University Düsseldorf, Germany
Trehalose-6-Phosphate Mediated Toxicity Determines Essentiality of OtsB2 in Mycobacterium Tuberculosis in vitro and in mice
Trehalose-6-Phosphate Mediated Toxicity Determines Essentiality of OtsB2 in Mycobacterium Tuberculosis in vitro and in mice
Lenette Lu,
Partners HealthCare, USA
Unique Functional Antibody Profiles in Latent and Active Tuberculosis Infection
Unique Functional Antibody Profiles in Latent and Active Tuberculosis Infection
Amanda J. Martinot,
Tufts Cummings School of Veterinary Medicine, USA
“Fat is not Fit”: Targeting Lipid Transport in Drug Discovery for Mycobacterium tuberculosis
“Fat is not Fit”: Targeting Lipid Transport in Drug Discovery for Mycobacterium tuberculosis
Amira Refai,
Institut Pasteur de Tunis, Tunisia
Discrepancy Around Biological Functions of Mycobacterium tuberculosis Virulent factor ESAT-6 is due to two Distinct Conformational States of the Protein
Discrepancy Around Biological Functions of Mycobacterium tuberculosis Virulent factor ESAT-6 is due to two Distinct Conformational States of the Protein
17:00—19:00
Pediatrics: Is Immaturity a Co-Morbidity?
*
Thomas J. Scriba,
University of Cape Town, South Africa
Theodore H. Cohen,
Yale School of Public Health, USA
Within-host Heterogeneity of M. tuberculosis Infection
Within-host Heterogeneity of M. tuberculosis Infection
Deborah Lewinsohn,
Oregon Health & Science University, USA
Pediatric Immunity in TB
Pediatric Immunity in TB
Helen McShane,
Jenner Institute, UK
Vaccine Immunogenicity and Correlates of Protection in Infants and Adults
Vaccine Immunogenicity and Correlates of Protection in Infants and Adults
Michael Shiloh,
University of Texas Southwestern Medical Center, USA
Short Talk: Airway Microfold Cells Translocate Mycobacterium Tuberculosis to Initiate Infection
Short Talk: Airway Microfold Cells Translocate Mycobacterium Tuberculosis to Initiate Infection
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Impact of Co-Infections on TB Pathogenesis
*
Shabaana Khader,
Washington University School of Medicine, USA
Alessandro Sette,
La Jolla Institute for Immunology, USA
Comprehensive Immunophenotyping and Immunoprofiling of Epitope-Specific Responses.
Comprehensive Immunophenotyping and Immunoprofiling of Epitope-Specific Responses.
Subash S. Babu,
National Institutes of Health - ICER, India
Modulation of Immune and Inflammatory Responses in Active Pulmonary Tuberculosis by Co-Incidental Helminth Infections
Modulation of Immune and Inflammatory Responses in Active Pulmonary Tuberculosis by Co-Incidental Helminth Infections
Padmini Salgame,
Rutgers University, USA
Helminth/TB Co-Infection: Th2 Cytokines
Helminth/TB Co-Infection: Th2 Cytokines
Maziar Divangahi,
McGill University, Canada
Influenza and Tuberculosis
Influenza and Tuberculosis
Jannike Blank,
Research Center Borstel, Germany
Short Talk: One Episode of Self-resolving Plasmodium yoelii Infection Transiently Exacerbates Chronic Mycobacterium tuberculosis Infection
Short Talk: One Episode of Self-resolving Plasmodium yoelii Infection Transiently Exacerbates Chronic Mycobacterium tuberculosis Infection
14:30—16:30
Workshop 3: Host-Directed Therapy
*
Alan Sher,
NIAID, National Institutes of Health, USA
Anna-Maria Andersson,
Linköping University, Sweden
Autophagy Enhances Mycobacterium tuberculosis Replication in Latently and HIV Co-Infected Human Macrophages
Autophagy Enhances Mycobacterium tuberculosis Replication in Latently and HIV Co-Infected Human Macrophages
Shashank Gupta,
Johns Hopkins University, USA
ONTAK, a Recombinant Toxin, as a Host-Directed Therapy for Tuberculosis in the Mouse Model
ONTAK, a Recombinant Toxin, as a Host-Directed Therapy for Tuberculosis in the Mouse Model
Stefan H. Oehlers,
Centenary Institute, Australia
Interception of Host Angiogenic Signaling Limits Mycobacterial Growth
Interception of Host Angiogenic Signaling Limits Mycobacterial Growth
Joseph Edward Qualls,
Cincinnati Children's Hospital Medical Center, USA
Macrophage L-citrulline Metabolism Improves Anti-Mycobacterial Host Defense in vivo
Macrophage L-citrulline Metabolism Improves Anti-Mycobacterial Host Defense in vivo
Robindra Basu Roy,
University of Oxford, UK
Evaluation of ibuprofen with Novel Whole Blood BCG GFP-luciferase Full Operon Assay
Evaluation of ibuprofen with Novel Whole Blood BCG GFP-luciferase Full Operon Assay
Javeed Ali Shah,
University of Washington, USA
TOLLIP Deficiency is Associated with Increased Mycobacterium tuberculosis-specific Anti-Microbial Monocyte Responses and Protection from Pediatric Tuberculosis in South Africa
TOLLIP Deficiency is Associated with Increased Mycobacterium tuberculosis-specific Anti-Microbial Monocyte Responses and Protection from Pediatric Tuberculosis in South Africa
17:00—19:15
Metabolism and Co-Morbidity II
*
Blanca I. Restrepo,
University of Texas HSC Houston, Brownsville Campus, USA
Megan Murray,
Harvard Medical School, USA
Diabetes and Environmental Co-Morbidities with TB
Diabetes and Environmental Co-Morbidities with TB
Hazel M. Dockrell,
London School Hygiene & Tropical Medicine, UK
Tuberculosis and Diabetes: Learning in TANDEM
Tuberculosis and Diabetes: Learning in TANDEM
Hardy Kornfeld,
University of Massachusetts Medical School, USA
Cellular Immunology of TB Susceptibility with Metabolic Co-Morbidities
Cellular Immunology of TB Susceptibility with Metabolic Co-Morbidities
Satyanarayana Swamy Cheekatla,
University of Texas Health N.E., USA
Short Talk: Nk-dc Crosstalk in Diabetes Enhances il-6 Mediated Inflammation during Tuberculosis Infection
Short Talk: Nk-dc Crosstalk in Diabetes Enhances il-6 Mediated Inflammation during Tuberculosis Infection
Anil Kumar Ojha,
Wadsworth Center, University at Albany, USA
Short Talk: Ribosomal Heterogeneity Determines Biofilm Development and Drug Tolerance in Mycobacteria
Short Talk: Ribosomal Heterogeneity Determines Biofilm Development and Drug Tolerance in Mycobacteria
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Host-Pathogen Interactions
*
Priscille Marie Brodin,
CIIL Institut Pasteur, France
Small Molecules Targeting Host Against M. tuberculosis
Small Molecules Targeting Host Against M. tuberculosis
Shabaana Khader,
Washington University School of Medicine, USA
Neutrophils in TB: The Good, the Bad and the Ugly
Neutrophils in TB: The Good, the Bad and the Ugly
Jeffery S. Cox,
University of California, Berkeley, USA
Discrimination of Pathogens from Non-Pathogens by Innate Immune Cells
Discrimination of Pathogens from Non-Pathogens by Innate Immune Cells
Joseph Keane,
Trinity College Dublin, Ireland
Effects of Cigarette Smoke on the Macrophage-Pathogen Interaction
Effects of Cigarette Smoke on the Macrophage-Pathogen Interaction
Jacqueline M. Kimmey,
Washington University, USA
Short Talk: Unique Role for ATG5 in PMN-Mediated Immunopathology during M. tuberculosis Infection
Short Talk: Unique Role for ATG5 in PMN-Mediated Immunopathology during M. tuberculosis Infection
Joanne Turner,
Texas Biomedical Research Instutite, USA
Short Talk: A Mouse Model of Age-Associated Tuberculosis Reactivation Positions KLRG1 as a Modulator of Disease Progression
Short Talk: A Mouse Model of Age-Associated Tuberculosis Reactivation Positions KLRG1 as a Modulator of Disease Progression
17:00—18:45
Host-Directed Therapeutics: Co-Opting Treatment of Co-Morbidities
*
Anna Kathleen Coussens,
Walter and Eliza Hall Institute, Australia
Amit Singhal,
Singapore Immunology Network, Singapore
Intervening Host Immunometabolic Program: Potential for TB HDT
Intervening Host Immunometabolic Program: Potential for TB HDT
Guy Edward Thwaites,
Oxford University Clinical Research Unit, Vietnam
Personalised Adjunctive Anti-Inflammatory Therapy for Tuberculosis
Personalised Adjunctive Anti-Inflammatory Therapy for Tuberculosis
Adrian R. Martineau,
Queen Mary University of London, UK
Vitamin D and Phenylbutyrate as Potential Host-Directed Therapies
Vitamin D and Phenylbutyrate as Potential Host-Directed Therapies
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
